Corporate Pharmaceuticals

iBio’s Machine Learning Model for Designing Engineered Epitopes Granted Patent

iBio has been issued a US patent for its machine learning model used to design engineered epitopes, which allow precise steering of therapeutic antibodies towards specific regions of a target […]

Read More
Pharmaceuticals Stock Market

iBio Announces Unaudited Preliminary Financial Results

iBio, Inc. (NYSEA:IBIO), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System, announced preliminary unaudited financial results for the fiscal year ended June 30, 2022, and provides […]

Read More